isatuximab plus dexamethasone, which did not reach statistical significance.
← all excerpts
Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments.
1
—
—
isatuximab plus dexamethasone, which did not reach statistical significance.